Hypertension: A Companion to Braunwald’s Heart Disease

  • William White, MD, Professor of Medicine, Center for Cardiology and Cardiovascular Biology, University of Connecticut School of Medicine, Farmington, CT, USA; Division Chief, Division of Hypertension and Clinical Pharmacology, University of Connecticut Health Center, Farmington, CT, USA
  • By

    • Henry Black, MD, Associate Vice President for Research, Charles J. and Margaret Roberts Professor; Chairman, Department of Preventive Medicine, Rush University Medical Center, Chicago, IL, USA
    • William Elliott, MD, PhD, Professor, Department of Preventive Medicine, Rush University Medical Center. Chicago, IL, USA

    Clinical hypertension is one of the most serious long-term problems associated with heart disease. This companion to Braunwald's Heart Disease focuses in depth on this key area of cardiovascular medicine. Complete with practical clinical tools for management, it helps you manage the chronic problems of your hypertensive patients. It covers everything from epidemiology and pathophysiology through diagnosis, risk stratification, treatment, outcome studies, concomitant diseases, special populations and special situations, and future treatments.
    View full description


    Cardiologists, cardiology fellows, and nephrologist


Book information

  • Published: November 2006
  • Imprint: SAUNDERS
  • ISBN: 978-1-4160-3053-9

Table of Contents

Section 1: Epidemiology & Pathophysiology

1. Epidemiology
2. Genetics of Hypertension
3. Pathogenesis of Hypertension

Section 2: Diagnosis

4. Definition of Hypertension
5. Measurement of Blood
6. Home BP Measurements
8. Secondary Hypertension: Renovascular Hypertension
9. Secondary Hypertension: Mineralocorticoid Excess States
10. Secondary Hypertension: Pheochromocytoma
11. Secondary Hypertension: Sleep Apnea
12. Rare Unusual Diagnoses

Section 3: Risk Stratification

13. Natural History of (Untreated) Hypertension
14. The Special Problem of (Isolated) Systolic Hypertension
15. Assessment of Target Organ Damage
16. Prediction of Global Cardiovascular Risk

Section 4: Treatment

17. Lifestyle Modifications
18. Diuretics
19. Beta-blockers
20. ACE-inhibitors and Angiotensin II Receptor Blockers
21. Calcium Antagonists
22. Alpha-Blockers
23. Other (Newer) Drugs, including centrally-acting drugs, aldosterone antagonists, vasopeptidase inhibitors, and endothelin antagonists

Section 5: Outcome Studies

24. Design of Outcomes Studies
25. Meta-analyses

Section 6: Hypertension and Concomitant Diseases

26. Ischemic Heart Disease
27. Heart Failure
28. Kidney Disease
29. Transplant Hypertension
30. Obesity
31. Peripheral Vascular Disease
32. Cerebrovascular Disease
33. Diabetes
34. Dyslipidemia

Section 7: Special Populations & Special Situations

35. Pregnancy-Related Hypertension
36. Children and Adolescents
37. Elderly
38. Blacks
39. Hispanics
40. East Asians
41. South Asians
42. Refractory Hypertension
43. Peri-operative Hypertension
44. Emergencies and Urgencies

Section 8: Hypertension Treatment in the Future

45. Hypertension Disease Management Service
46. Hypertension Genomics
47. Approval Process for Antihypertensive Drugs—US and International

Section 9: Guidelines

48. US and Canadian Guidelines
49. European Guidelines, including BHS and ESH/ESC